Organic Acid Precipitation for Coagulation Factor Removal

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for removing or inactivating coagulation factors like FXIa from protein preparations are time-consuming and costly, particularly when using chromatography, and there is a risk of unwanted clot formation in therapeutic applications.

Innovation Solution

A method involving the use of organic acids or their salts, such as caprylic acid, to inactivate or remove coagulation factors FXIa, FII, FVII, FVIIa, FIX, FIXa, and FX from solutions containing immunoglobulins or albumin, by stirring at specific temperatures and pH ranges, allowing for the separation of precipitates and subsequent filtration or centrifugation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If chromatography methods are used to remove coagulation factors, then purification effectiveness is improved, but processing time and cost increase

Engineering Contradiction:
Improvepurification effectivenessVSAvoidprocessing time
Core Design Contradiction:
Manufacturing precisionVSLoss of time

Solution Approach 1:

The patent changes the chemical parameters of the solution by adjusting pH to specific ranges (pH 3.5-6.0) and introducing organic acids or their salts, which alters the solubility and precipitation behavior of coagulation factors, enabling their selective removal without chromatography

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent extracts coagulation factors from the protein solution through selective precipitation caused by organic acid addition. The coagulation factors precipitate out of solution while therapeutic proteins remain soluble, allowing separation by simple filtration or centrifugation

Inventive Principle:
Principle #2Taking out (Extraction)

2Manufacturing precision

If chromatography methods are used to remove coagulation factors, then purification effectiveness is improved, but manufacturing cost increases

Engineering Contradiction:
Improvepurification effectivenessVSAvoidmanufacturing cost
Core Design Contradiction:
Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent replaces expensive chromatography resins with inexpensive organic acids (such as acetic acid, propionic acid, butyric acid, or their salts) that can be easily added and removed. These cheap reagents achieve the same purification effect without requiring costly specialized materials

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent extracts coagulation factors through selective precipitation using organic acids, eliminating the need for expensive chromatography columns and resins while achieving comparable or superior purification effectiveness

Inventive Principle:
Principle #2Taking out (Extraction)

3Ease of operation

If coagulation factors are not removed, then processing simplicity is maintained, but safety risk increases due to thrombotic events

Engineering Contradiction:
Improveprocessing simplicityVSAvoidthrombotic risk
Core Design Contradiction:
Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The patent extracts coagulation factors through selective precipitation, effectively removing the harmful procoagulant activity while maintaining a simple processing approach that avoids complex chromatography

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes solution parameters (pH, organic acid concentration) to selectively precipitate coagulation factors, achieving safe removal of thrombotic risk factors through a simple, controllable process

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method effectively reduces coagulation factors to undetectable levels, preventing procoagulant activity and ensuring the safety of therapeutic preparations by eliminating the risk of thrombotic events, with the ability to integrate into existing protein purification processes.

Implementation Method 1

contacting a coagulation factor containing immunoglobulin G (IgG) solution with an organic acid or its salt while being stirred at a temperature from about 0° C. to about 40° C., in the pH range from about 3.5 to about 6.0, not only inactivated or removed FXIa but also other coagulation factors

Methodology Applied
Scientific EffectSelective precipitation: Precipitation

Data Source

PatentUS10640548B2Method for inactivation/removal of coagulation factors by precipitation
Publication Date: 2020.05.05 OCTAPHARMA AG

AI summary

A method for inactivation or removal of coagulation factors FII, FVII, FVIIa, FIX, FIXa, FX, FXI and FXIa in or from protein containing solutions obtained from blood, blood plasma, plasma fractions or by recombinant means wherein the protein containing solution is contacted with an organic acid or its salt while being stirred.